# Shire PLC label expansion of Cinryze

- Link: https://www.directorstalkinterviews.com/shire-plc-label-expansion-cinryze/412753213
- Published: 2018-06-21T07:27:18+01:00
- Author: Charlotte Edwards

**Shire PLC** (LON:SHP) has today announced the approval of label expansion of Cinryze.

CINRYZE is the first and only therapy indicated in the U.S. to help prevent angioedema
attacks in pediatric patients with hereditary angioedema (HAE) as young as 6
 Shire
is the only drug developer to complete a pediatric study for the prophylactic treatment
of HAE HAE is a rare, genetic disorder that causes debilitating, painful and sometimes
life-threatening swelling in the body Dublin, Ireland – Thursday, June 21, 2018 –
Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global biotechnology company focused
on rare diseases, today announced that the U.S. Food and Drug Administration (FDA)
has approved a label expansion for CINRYZE® (C1 esterase inhibitor [human]), making
it available to help prevent angioedema attacks in children aged 6 years and older
with hereditary angioedema (HAE). CINRYZE has been approved in the U.S. since October
2008 for routine prophylaxis against attacks in adolescents and adults living with
HAE.[1]

HAE is a rare, genetic disorder estimated to affect about 1 in 10,000 to 1 in 50,000
people worldwide.[2],[3] The condition results in recurring attacks of edema (swelling)
in various parts of the body, including the abdomen, face, feet, genitals, hands
and throat that can be can debilitating and painful.2,[4],[5] Attacks that obstruct
the airways (laryngeal attacks) are potentially life-threatening due to the risk
of asphyxiation.2,4,5

> **Andreas Busch, Ph.D., Executive Vice President, Head of Research and Development
> at Shire said:** “Symptoms of HAE often present in childhood with the average 
> child experiencing their first HAE attack around the age of 10.[6] With the FDA
> label expansion of CINRYZE, children as young as 6 years old living with HAE now
> have the first FDA approved treatment option available to help prevent attacks.”

The approval was based on data from a dedicated Phase 3 multicenter single-blind
study (0624-301) that evaluated the use of CINRYZE in 12 patients living with HAE
aged 7 to 11. Compared to the baseline observational period, the mean reduction 
in the normalized number of attacks for CINRYZE 500 U and CINRYZE 1,000 U was 71.1%
and 84.5%, respectively. Both doses lessened the severity of attacks and reduced
the use of acute treatment compared to baseline. The adverse reactions were headache,
nausea, pyrexia (fever), and infusion site erythema (redness of the skin). None 
of these adverse reactions were severe, and none led to discontinuation (n=12, ages
7-11).1

> **Anthony Castaldo, President of the U.S. Hereditary Angioedema Association said:**“
> This news is exciting for the HAE community because those living with HAE who 
> are as young as 6 have a new option to help prevent attacks,”

In March 2017, CINRYZE was granted European Commission (EC) approval for the label
expansion granting three new indications, including routine prevention of angioedema
attacks in children (ages 6 years and above) with severe and recurrent attacks of
HAE.[7]

**About the CINRYZE Pediatric Study**
 Study 0624-301 was a Phase 3 multicenter,
single-blind study that enrolled 12 patients aged 7 to 11 with HAE who were required
to have an average of greater than or equal to1.0 angioedema attacks per month that
were moderate, severe, or required acute treatment during the 12-week baseline observation
period. Patients received 500 U and 1000 U of CINRYZE every 3-4 days for 12 weeks.
The primary efficacy endpoint was the monthly-normalized number of attacks.

Overall the safety and tolerability of CINRYZE has been shown to be similar in clinical
studies of pediatric, adolescent and adult patients with HAE.

**About CINRYZE**
 CINRYZE is currently approved for routine prophylaxis against
angioedema attacks in children aged 6 years and older, adolescent and adult patients
with HAE. The active substance in CINRYZE is C1-Esterase Inhibitor (C1-INH), which
raises plasma levels of C1-INH in patients with HAE, who are prone to swelling due
to an underlying deficiency in C1-INH. Treatment with C1-INH addresses the underlying
cause of HAE by replacing the deficient protein and helps regulate the production
of bradykinin released during an attack. CINRYZE was the first C1-INH proven to 
help prevent swelling attacks in those living with HAE.1

In Europe, CINRYZE is the first and only C1-Esterase Inhibitor (C1-INH) therapy 
approved for routine prevention in children, adolescents, and adults with HAE. CINRYZE
is also approved for acute treatment and pre-procedure prevention of angioedema 
attacks.

Share on:
